Do analysts rate LIMN or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, LIMN or ALVR?

Liminatus Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is LIMN or ALVR more profitable?

Liminatus Pharma's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% AlloVir N/A -71.03% -61.27%

Do analysts prefer AYTU or LIMN?

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 382.06%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aytu BioPharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate LIMN or MDCX?

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,365.75%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Medicus Pharma 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has better earnings and valuation, LIMN or MDCX?

Liminatus Pharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Medicus Pharma N/A N/A -$35.46M -$2.68 N/A

Is LIMN or MDCX more profitable?

Liminatus Pharma's return on equity of 0.00% beat Medicus Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Medicus Pharma N/A -3,137.84% -311.33%

Do analysts recommend LIMN or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer LIMN or NRSN?

NeuroSense Therapeutics has a consensus price target of $8.50, indicating a potential upside of 1,097.18%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Liminatus Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable valuation & earnings, LIMN or NRSN?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is LIMN or NRSN more profitable?

Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% NeuroSense Therapeutics N/A N/A N/A

Liminatus Pharma (LIMN) Competitors

$0.12 +0.01 (+14.01%)

As of 02:41 PM Eastern

Compare

LIMN vs. ALVR, AYTU, MDCX, TXMD, and NRSN

Should you buy Liminatus Pharma stock or one of its competitors? MarketBeat compares Liminatus Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Liminatus Pharma include AlloVir (ALVR), Aytu BioPharma (AYTU), Medicus Pharma (MDCX), TherapeuticsMD (TXMD), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical products" industry.

How does Liminatus Pharma compare to AlloVir?

Liminatus Pharma (NASDAQ:LIMN) and AlloVir (NASDAQ:ALVR) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Liminatus Pharma has a beta of 5.62, meaning that its share price is 462% more volatile than the broader market. Comparatively, AlloVir has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Liminatus Pharma is trading at a lower price-to-earnings ratio than AlloVir, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Liminatus Pharma's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
AlloVir	N/A	-71.03%	-61.27%

66.1% of AlloVir shares are held by institutional investors. 32.1% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Liminatus Pharma had 1 more articles in the media than AlloVir. MarketBeat recorded 1 mentions for Liminatus Pharma and 0 mentions for AlloVir. Liminatus Pharma's average media sentiment score of 1.87 beat AlloVir's score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
AlloVir	Neutral

Summary

Liminatus Pharma beats AlloVir on 7 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to Aytu BioPharma?

Aytu BioPharma (NASDAQ:AYTU) and Liminatus Pharma (NASDAQ:LIMN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

Liminatus Pharma has lower revenue, but higher earnings than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$56.60M	0.42	-$13.56M	-$4.58	N/A
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 1.87 equaled Liminatus Pharma'saverage media sentiment score.

Company	Overall Sentiment
Aytu BioPharma	Very Positive
Liminatus Pharma	Very Positive

33.5% of Aytu BioPharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Aytu BioPharma has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market. Comparatively, Liminatus Pharma has a beta of 5.62, suggesting that its stock price is 462% more volatile than the broader market.

Aytu BioPharma currently has a consensus price target of $10.75, suggesting a potential upside of 382.06%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Liminatus Pharma has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. Liminatus Pharma's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Liminatus Pharma	N/A	N/A	-299.79%

Summary

Aytu BioPharma beats Liminatus Pharma on 7 of the 13 factors compared between the two stocks.

How does Liminatus Pharma compare to Medicus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Medicus Pharma (NASDAQ:MDCX) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, media sentiment, profitability, risk and earnings.

In the previous week, Medicus Pharma had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for Medicus Pharma and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.87 beat Medicus Pharma's score of 1.43 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
Medicus Pharma	Positive

Liminatus Pharma is trading at a lower price-to-earnings ratio than Medicus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Medicus Pharma	N/A	N/A	-$35.46M	-$2.68	N/A

Liminatus Pharma's return on equity of 0.00% beat Medicus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Medicus Pharma	N/A	-3,137.84%	-311.33%

Medicus Pharma has a consensus price target of $9.00, indicating a potential upside of 2,365.75%. Given Medicus Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Medicus Pharma is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Medicus Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Liminatus Pharma has a beta of 5.62, meaning that its stock price is 462% more volatile than the broader market. Comparatively, Medicus Pharma has a beta of -0.05, meaning that its stock price is 105% less volatile than the broader market.

Summary

Liminatus Pharma beats Medicus Pharma on 6 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to TherapeuticsMD?

Liminatus Pharma (NASDAQ:LIMN) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Liminatus Pharma has a beta of 5.62, meaning that its share price is 462% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market.

TherapeuticsMD has higher revenue and earnings than Liminatus Pharma. Liminatus Pharma is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
TherapeuticsMD	$3.35M	6.77	-$570K	$0.06	32.67

TherapeuticsMD has a net margin of 5.34% compared to Liminatus Pharma's net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Liminatus Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
TherapeuticsMD	5.34%	0.32%	0.23%

30.7% of TherapeuticsMD shares are held by institutional investors. 1.7% of TherapeuticsMD shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Liminatus Pharma and Liminatus Pharma both had 1 articles in the media. TherapeuticsMD's average media sentiment score of 1.89 beat Liminatus Pharma's score of 1.87 indicating that TherapeuticsMD is being referred to more favorably in the news media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
TherapeuticsMD	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

TherapeuticsMD beats Liminatus Pharma on 10 of the 11 factors compared between the two stocks.

How does Liminatus Pharma compare to NeuroSense Therapeutics?

Liminatus Pharma (NASDAQ:LIMN) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, earnings, risk, profitability, dividends, valuation and analyst recommendations.

NeuroSense Therapeutics has a consensus price target of $8.50, indicating a potential upside of 1,097.18%. Given NeuroSense Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe NeuroSense Therapeutics is more favorable than Liminatus Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

Liminatus Pharma has a beta of 5.62, indicating that its share price is 462% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
NeuroSense Therapeutics	N/A	N/A	N/A

In the previous week, NeuroSense Therapeutics had 1 more articles in the media than Liminatus Pharma. MarketBeat recorded 2 mentions for NeuroSense Therapeutics and 1 mentions for Liminatus Pharma. Liminatus Pharma's average media sentiment score of 1.87 beat NeuroSense Therapeutics' score of 1.13 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Very Positive
NeuroSense Therapeutics	Positive

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 27.4% of NeuroSense Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

NeuroSense Therapeutics beats Liminatus Pharma on 8 of the 13 factors compared between the two stocks.

Get Liminatus Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LIMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LIMN vs. The Competition

Export

Metric	Liminatus Pharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$6.17M	$621.21M	$4.38B	$12.65B
Dividend Yield	N/A	N/A	30.61%	8.43%
P/E Ratio	-0.28	N/A	23.75	24.40
Price / Sales	N/A	397.98	147.12	91.46
Price / Cash	N/A	N/A	165.47	59.39
Price / Book	-0.33	2.75	12.31	6.33
Net Income	-$10.21M	-$75.73M	$120.20M	$331.45M
7 Day Performance	-4.07%	-3.68%	-0.77%	0.18%
1 Month Performance	-1.75%	21.43%	-2.84%	-0.72%
1 Year Performance	-97.89%	-78.42%	11.37%	20.53%

Liminatus Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LIMN Liminatus Pharma	0.4594 of 5 stars	$0.12 +14.0%	N/A	-98.4%	$6.17M	N/A	N/A	N/A	Positive News High Trading Volume
ALVR AlloVir	N/A	$4.71 -2.5%	N/A	+81.9%	$23.75M	N/A	N/A	110	High Trading Volume
AYTU Aytu BioPharma	2.7472 of 5 stars	$2.19 +0.3%	$10.75 +391.5%	+2.3%	$23.67M	$66.38M	N/A	160
MDCX Medicus Pharma	3.5583 of 5 stars	$0.42 -2.9%	$9.00 +2,063.5%	-88.4%	$23.57M	N/A	N/A	N/A	Positive News Short Interest Decrease
TXMD TherapeuticsMD	1.3164 of 5 stars	$1.99 +1.0%	N/A	+68.4%	$23.02M	$3.02M	33.17	420

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LIMN) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Liminatus Pharma (LIMN) Competitors

LIMN vs. ALVR, AYTU, MDCX, TXMD, and NRSN

How does Liminatus Pharma compare to AlloVir?

Summary

How does Liminatus Pharma compare to Aytu BioPharma?

Summary

How does Liminatus Pharma compare to Medicus Pharma?

Summary

How does Liminatus Pharma compare to TherapeuticsMD?

Summary

How does Liminatus Pharma compare to NeuroSense Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Liminatus Pharma (LIMN) Competitors

LIMN vs. ALVR, AYTU, MDCX, TXMD, and NRSN

How does Liminatus Pharma compare to AlloVir?

Do analysts rate LIMN or ALVR?

Which has more volatility and risk, LIMN or ALVR?

Which has stronger earnings and valuation, LIMN or ALVR?

Is LIMN or ALVR more profitable?

Do insiders and institutionals hold more shares of LIMN or ALVR?

Does the media favor LIMN or ALVR?

Summary

How does Liminatus Pharma compare to Aytu BioPharma?

Which has higher valuation & earnings, AYTU or LIMN?

Does the media refer more to AYTU or LIMN?

Do institutionals & insiders have more ownership in AYTU or LIMN?

Which has more volatility & risk, AYTU or LIMN?

Do analysts prefer AYTU or LIMN?

Is AYTU or LIMN more profitable?

Summary

How does Liminatus Pharma compare to Medicus Pharma?

Does the media prefer LIMN or MDCX?

Which has better earnings and valuation, LIMN or MDCX?

Is LIMN or MDCX more profitable?

Do analysts rate LIMN or MDCX?

Which has more risk & volatility, LIMN or MDCX?

Summary

How does Liminatus Pharma compare to TherapeuticsMD?

Which has more volatility and risk, LIMN or TXMD?

Which has better earnings & valuation, LIMN or TXMD?

Is LIMN or TXMD more profitable?

Do insiders and institutionals have more ownership in LIMN or TXMD?

Does the media favor LIMN or TXMD?

Do analysts recommend LIMN or TXMD?

Summary

How does Liminatus Pharma compare to NeuroSense Therapeutics?

Do analysts prefer LIMN or NRSN?

Which has preferable valuation & earnings, LIMN or NRSN?

Which has more volatility & risk, LIMN or NRSN?

Is LIMN or NRSN more profitable?

Does the media refer more to LIMN or NRSN?

Do institutionals and insiders believe in LIMN or NRSN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIMN vs. The Competition

Liminatus Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools